Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
- Conditions
- Hemophagocytic Lymphohistiocytosis
- Interventions
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 31
- Registration Number
- NCT01104025
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Drug: CarboplatinDrug: EtoposideBiological: FilgrastimDrug: IfosfamideProcedure: LeukapheresisDrug: PlerixaforBiological: Rituximab
- First Posted Date
- 2010-04-01
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01097057
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
- Conditions
- Clear Cell EpendymomaPapillary EpendymomaAnaplastic EpendymomaCellular EpendymomaEpendymomaBrain Ependymoma
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyDrug: CarboplatinOther: Clinical ObservationDrug: CyclophosphamideDrug: CisplatinDrug: EtoposideBiological: FilgrastimOther: Laboratory Biomarker AnalysisDrug: MesnaDrug: Vincristine
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 479
- Registration Number
- NCT01096368
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- LeukemiaOral ComplicationsMucositis
- Interventions
- Biological: rituximabBiological: paliferminDrug: cyclophosphamideProcedure: allogeneic hematopoietic stem cell transplantationDrug: cytarabineDrug: daunorubicin hydrochlorideRadiation: total-body irradiationDrug: etoposideDrug: fludarabine phosphateDrug: imatinib mesylateDrug: melphalanDrug: mercaptopurineDrug: methotrexateDrug: nelarabineDrug: pegaspargaseDrug: vincristine sulfate
- First Posted Date
- 2010-03-12
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- University College, London
- Target Recruit Count
- 1033
- Registration Number
- NCT01085617
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 16
- Registration Number
- NCT01084759
- Locations
- 🇺🇸
Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
- Conditions
- Stage IIIA Non-small Cell Lung Cancer
- Interventions
- Radiation: proton beam radiation therapyDrug: cisplatinDrug: etoposideProcedure: therapeutic conventional surgery
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 34
- Registration Number
- NCT01076231
- Locations
- 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 21
- Registration Number
- NCT01059071
- Locations
- 🇺🇸
Connecticut Children's Hospital, Hartford, Connecticut, United States
🇺🇸Levine Children's Hospital, Charlotte, North Carolina, United States
🇺🇸UVM/FAHC, Burlington, Vermont, United States
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple MyelomaPlasma Cell Myeloma
- Interventions
- Drug: bortezomibDrug: cisplatinDrug: cyclophosphamideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: etoposideDrug: lenalidomideDrug: melphalanDrug: thalidomideGenetic: gene expression analysisGenetic: microarray analysisOther: laboratory biomarker analysisProcedure: autologous-autologous tandem hematopoietic stem cell transplantation
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT01055301
- Locations
- 🇺🇸
Harborview Medical Center, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Group Health Central Hospital, Seattle, Washington, United States
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
- Conditions
- Untreated Childhood RhabdomyosarcomaChildhood Alveolar RhabdomyosarcomaChildhood Embryonal RhabdomyosarcomaAdult RhabdomyosarcomaMetastatic Childhood Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
- Interventions
- Biological: CixutumumabBiological: DactinomycinDrug: CyclophosphamideDrug: EtoposideDrug: Doxorubicin HydrochlorideDrug: IfosfamideDrug: Irinotecan HydrochlorideOther: Laboratory Biomarker AnalysisDrug: TemozolomideDrug: Vincristine Sulfate Liposome
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 175
- Registration Number
- NCT01055314
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States
Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma
- Conditions
- Recurrent Non-Hodgkin LymphomaAnaplastic Large Cell Lymphoma, ALK-NegativeRecurrent Anaplastic Large Cell LymphomaRecurrent Transformed Non-Hodgkin LymphomaRecurrent Mantle Cell LymphomaRecurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarmustineDrug: CytarabineDrug: EtoposideDrug: LenalidomideDrug: MelphalanBiological: Rituximab
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 74
- Registration Number
- NCT01035463
- Locations
- 🇺🇸
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.